ClinVar Miner

Submissions for variant NM_000349.3(STAR):c.653C>T (p.Ala218Val)

gnomAD frequency: 0.00003  dbSNP: rs137852690
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001388088 SCV001588935 pathogenic not provided 2023-11-10 criteria provided, single submitter clinical testing This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 218 of the STAR protein (p.Ala218Val). This variant is present in population databases (rs137852690, gnomAD 0.008%). This missense change has been observed in individuals with congenital lipoid adrenal hyperplasia (PMID: 9097960, 10566637, 23748066). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 8993). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects STAR function (PMID: 9097960). For these reasons, this variant has been classified as Pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000009556 SCV002511480 pathogenic Congenital lipoid adrenal hyperplasia due to STAR deficency 2022-04-14 criteria provided, single submitter clinical testing Variant summary: STAR c.653C>T (p.Ala218Val) results in a non-conservative amino acid change located in the START domain (IPR002913) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. 4/4 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 4e-05 in 251340 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in STAR causing Congenital Lipoid Adrenal Hyperplasia (4e-05 vs 0.0035), allowing no conclusion about variant significance. c.653C>T has been reported in the literature as homozygous and compound heterozygous genotypes in multiple individuals affected with Congenital Lipoid Adrenal Hyperplasia (example, Kang_2017, Wijaya_2021, Nakae_1997). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function (Nakae_1997). The most pronounced variant effect results in <10% of normal activity. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
3billion RCV000009556 SCV002572582 pathogenic Congenital lipoid adrenal hyperplasia due to STAR deficency 2022-09-01 criteria provided, single submitter clinical testing The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.004%). Functional studies provide strong evidence of the variant having a damaging effect on the gene or gene product (PMID: 9097960). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.76; 3Cnet: 0.68). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (PMID: VCV000008993). A different missense change at the same codon (p.Ala218Thr) has been reported to be associated with STAR-related disorder (PMID: 31666050). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline.
OMIM RCV000009556 SCV000029774 pathogenic Congenital lipoid adrenal hyperplasia due to STAR deficency 1999-11-01 no assertion criteria provided literature only
Natera, Inc. RCV000009556 SCV002083261 pathogenic Congenital lipoid adrenal hyperplasia due to STAR deficency 2020-10-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.